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The incidence of nonmelanoma skin cancer con-
tinues to rise with over 1.3 million cases diagnosed in the
United States in 2002.[1] Squamous cell carcinoma
(SCC), the second most common human cancer,
accounts for 250,000 cancers diagnosed in the U.S.
annually. In the majority of cases, cure is achieved,
however there are subsets of patients in whom SCCs
behave aggressively and in whom SCC can be
devastating.[2] This is particularly true in the case of
organ transplant recipients (OTRs).[3]
There are over 100,000 OTRs currently living in the
United States.[4] Over 25,000 transplants are performed
in the U.S. annually with the large majority being renal
transplants.[5] Transplant recipients are living longer
with the half life of renal grafts reaching 20 years[6,7]
and the 5 – year survival rate for heart transplant recipi-
ents approaching 80%.[8] 
Epidemiology
OTRs are at significantly increased risk for develop-
ing skin cancers, particularly SCC.[4,9,10] OTRs are
also at increased risk for Kaposi’s sarcoma, Melanoma,
and BCC.[4,9,10] Skin cancer is a cause of significant
morbidity and even mortality in transplant patients.
Seventy percent of transplant patients may eventually
develop skin cancer with an increased SCC:BCC
ratio.[10-17] In a study of 5356 consecutive patients
transplanted between 1970 and 1994, NMSC other than
BCC occurred in 172 patients.[18] Relative risk was
~109 for men and ~93 for women. 
Kidney Transplantation and Skin Cancer
Jensen, et al, studied skin cancer in a Norwegian
cohort that included over 2500 transplant recipients.[16]
In this study, OTRs had increased risk for cutaneous
SCC (65-fold), malignant melanoma (3-fold), and SCC of
the lip (20-fold). Risk for skin cancer was higher (~20:1)
in patients transplanted after age 60 and for those on
triple immunosuppression. Kidney transplant patients
were at lower risk for skin cancer than heart transplant
patients. Kidney transplant recipients on cyclosporine,
azathioprine, and prednisolone had a ~3 fold increased
risk for developing cutaneous SCC relative to those
receiving azathioprine and prednisolone without
cyclosporine. Naldi, et al, reviewed 1062 kidney trans-
plant recipients and showed a cumulative skin cancer
incidence of nearly 6% at 5 years and over 10% at 10
years.[17] Older age at transplant and male sex favored
development of skin cancer. In contrast to other studies,
there was no difference in risk between kidney and heart
transplant recipients. The SCC:BCC ratio was 1:2.6 for
kidney transplant patients. 
Euvrard, et al, reviewed skin cancer development in a
series that included 580 kidney transplant patients.[11]
Kidney transplant recipients were half as likely to devel-
op skin cancer as heart transplant recipients. Kidney
transplant patients were younger at transplant, received
less intense immunosuppression, and had a longer inter-
val between transplant and first skin cancer. The
SCC:BCC ratio was 2.37:1 in kidney transplant recipi-
ents.
Heart Transplantation and Skin Cancer
In the study by Jensen, et al, heart transplant recipi-
ents were 3 times more likely to develop SCC than
kidney transplant patients. Lampros, et al, reported on
248 heart transplant patients followed between 1985 and
1996.[13] Forty one patients (17%) developed 192 SCCs
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or BCCs. SCC accounted for ~90% of the skin malig-
nancies (172) with the SCC:BCC ratio approaching 9:1.
Two patients in this study developed metastases from
primary cutaneous SCC. Skin cancer risk was associat-
ed with increased time after transplant, use of OKT3,
male sex (~20:1), blue eyes, and fair skin. 
In a study of heart transplant patients from Spain by
Espana, et al, skin cancer was diagnosed in 14 of 92
patients between 1984 and 1993.[10] The risk for skin
cancer rose from 4.8% in the first year after transplanta-
tion to 43.8% at seven years. Skin cancers occurred
primarily in patients with skin types II and III. Interesting-
ly the SCC:BCC ratio was 1.3:1. Four of the 14 patients
developed SCC of the lip and 1 died of metastatic
disease.
Ong, et al, (1999), reviewed skin cancers in 455
Australian heart transplant patients and found a cumula-
tive incidence of 31% at 5 years and 43% at 10
years.[15] In this study, skin cancer accounted for 27%
of 41 deaths after the fourth year following transplanta-
tion. SCCs were the most common cancers in this group
outnumbering BCCs by a ratio of 3:1. Fair skin,
increased age at transplant, and increased length of time
after transplant were associated with greatest risk of
developing skin cancer in this study.
The development of aggressive cutaneous malignan-
cy after cardiothoracic transplant (CTT) was addressed
by Venes, et al, in a study of 619 patients who received
heart, lung, or heart –lung transplants between 1984 and
1995.[14] Aggressive skin cancer, including locally
invasive SCC, recurrent SCC, poorly differentiated SCC,
and regionally metastatic SCC, occurred in 27 of 66 
(~ 41%) patients diagnosed with a malignancy. There
were 10 deaths from metastatic disease. 
Liver Transplantation and Skin Cancer 
The incidence of skin cancer was 1.6% a series of
liver transplant recipients by Levy[12] with a single case
of metastases from primary skin cancer. In a study by
Frezza, et al, 50 of 1657 liver transplant recipients devel-
oped tumors.[19] Skin cancers were most common with
the SCC:BCC ratio approaching 1:1. A higher incidence
of cancer was observed in patients treated with
cyclosporine as opposed to tacrolimus.
Pathogenesis at the Molecular Level
P53 is key in epidermal cell apoptosis following UV
radiation-mediated DNA damage.[20,21] Ultraviolet light
(UVL) serves as an initiator as well as a tumor promoter
[20,22] and p53 dependent apoptosis of sun-damaged
cells is believed to protect against SCC. Mutations in p53
including formation of thymidine dimers are seen in AKs
(70%) and SCC (90%).[22]
Mutant p53 tends to accumulate in the cytoplasm
whereas wild type p53 tends to be degraded rapidly.[21]
Some theorize that over expression of mutant p53 might
contribute to tolerance.[23]
Ras GTPases regulate cell proliferation, angiogene-
sis, apoptosis, and cellular morphology.[23] Ras and
Raf, a downstream effector molecule, stimulate cell
division, inhibit differentiation, and enhance expression
of integrins, all changes characteristic of SCC.[24] The
cascade involving Ras and downstream effector
molecules might be a viable target for attacking SCC on
the molecular level. 
The NF-kB family refers to conserved transcription
factors implicated in regulation of apoptosis, differentia-
tion and proliferation.[24] Blockade stimulates hyperpro-
liferation in human epidermis in vitro. Mice with inhibited
NF-kB show increased susceptibility to induction of
SCC.[25] Blockade along with induction of oncogenic
Ras can transform human epidermis to a highly aggres-
sive neoplasia indistinguishable from SCC.[26] 
The cDNK2A locus on 9p21 is widely mutated in a
number of cancers.[23] It encodes a cyclin depenent
kinase (CDK) inhibitor, p16[INK4A], and a p53 regulator
that is translated by an alternative reading frame. The
p16[INK4A] inhibits cell cycle progression in G1 by
binding and inhibiting CDK4/6 kinases. CDK4/6 kinases
phosphorylate retinoblastoma (Rb) proteins to remove
the mid-G1 Rb block to cell cycle progression.[23]
DNK4/6 is over expressed in SCC and is sufficient to
induce SCC when co-expressed with oncogenic Ras.[27]
Gene Expression and Cancer 
Microarray techniques allow for analysis of differential
gene expression between diseased and normal tissue.
With careful interpretation investigators may be able to
identify key differences in gene expression that may lead
to better risk stratification and novel points for therapeu-
tic intervention. Preliminary unique gene expression
patterns have been observed in head and neck
squamous cell carcinoma (HNSCC).[28]
Such a molecular fingerprint has yet to be established
for cutaneous SCC however this is the subject of
ongoing collaborative efforts involving the Laboratory of
Investigative Dermatology at the Rockefeller University
and the Section of Mohs Micrographic and Dermatologic
Surgery at the Weill Medical College of Cornell. Present-
ly, several studies support the importance of differential
expression of key genes in SCC and SCC cell lines. In
one pilot study, p16[INK4A] was 85% sensitive and 96%
specific in distinguishing Bowen’s disease from AK.[29]
Dazard, et al, studied the response of normal
keratinocytes and SCC to UVB and found up-regulation
of CXC/CC chemokines, growth factors, pro-inflammato-
ry mediators including S100A9, DNA repair genes, and
proteases including MMP1 and MMP 10.[30] They found
that Delta Np63 and PUMILIO, potential markers for
maintenance of keratinocytes stem cells, were down-
regulated. Gariboldi, et al, found that the serpin like
SCCA2 was associated with younger onset in 2 series of
patients with cutaneous SCC.[31] 
Environmental and Inherited Factors Involved
in Pathogenesis
The pathogenesis of skin cancer in the general
population and in organ transplant recipients involves
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ultraviolet light (UVL).[32] Tumor initiation occurs
through UV induced genetic changes in keratinocytes
DNA.[20,32] In addition, UV specific changes take place
in tumor suppressor p53. Thus UVL acts as both tumor
initiator and tumor promoter.[20,32] 
HPV is involved in the pathogenesis of SCC.[33] HPV
types 6, 11, 16 and 18 have been associated with cervi-
cal cancers.[34] HPV types 5 and 8 are associated with
epidermodysplasia verruciformis.[35] HPV 16 has been
implicated in SCC occurring on the digits.[36] HPV 16
and 18 have associated E6 and E7 proteins that inhibit
tumor suppressor p53.[37] In addition it has been shown
that E6 may inhibit UV induced apoptosis by a p53
independent mechanism thus acting as a p53 indepen-
dent tumor promoter by allowing propagation of atypical
keratinocytes. Furthermore it has been shown that EDV
associated HPV types are found in SCCs from
OTRs.[38] This is in agreement with Stockfleth, et al,
who recently showed that HPV DNA was detected more
frequently in SCCs from OTRs compared to non-OTRs
(75% vs 37%) and that HPV 5 and 8 were detected most
frequently in SCCs from transplant recipients.[39]
Euvrard, et al, examined warts, actinic keratoses and
SCCs from renal transplant recipients for the presence of
HPV types 1a, 2a, 5, 16, and 18.[40] HPV DNA was
detected in 44 of 86 specimens overall including 14 of 17
warts, 4 of 17 actinic keratoses, and 14 of 30 SCC.
Benign types 1 and 2 were detected in 5 SCC. 
Opinion differs as to whether certain HLA types
confer protection or risk.[10,15,16] There was no associ-
ation with haplotypes HLA-A3, HLA-A11, HLA-DR and
mismatches for HLA-B in the study of heart transplant
patients by Espana, et, al. In contrast, HLA-DR homozy-
gosity was associated with skin cancer and HLA-DR7,
HLA-A1 and HLA-A11 seemed to be protective in a study
by Ong. Major factors associated with increased risk for
skin cancer are summarized in Table 1.
Immunosuppression and Skin Cancer
Immunosuppression is key to preventing graft rejec-
tion and optimizing graft survival. However, immunosup-
pressive regimens have been associated with increased
rates of skin cancer. Studies suggest that both azathio-
prine and cyclosporine contribute to increased risk for
skin cancer through direct carcinogenic effects as well as
decreased immunosurveillance.[4,41-44] Intensity and
duration of immune suppression appear to correlate with
risk of aggressive SCC.[4] 
Azathioprine inhibits T and B cell proliferation by
inhibiting nucleotide synthesis.[45] It is a mutagen, a
photosensitizer and an immunosuppressant. A metabo-
lite of azathioprine, 6-thioguanine has been found in
higher concentrations in red blood cells from renal trans-
plant recipients with skin cancer.[46] Azathioprine has
been associated with high numbers of UV induced
tumors in animals.[47]
Cyclosporine inhibits IL-2 transcription, enhances
TGF-β expression and thus inhibits T cell function.[48]
Animal studies support direct carcinogenesis by
cyclosporine.[49] Cyclosporine has been associated with
tumor growth in SCID mice.[50] Cyclosporine induced
carcinogenesis was blocked by antibody to TGF-β impli-
cating TGF-β in cyclosporine induced carcinogenesis.
Cyclosporine has been shown to enhance invasive
tumors in vitro and to promote the growth of transplant-
ed UV induced tumors in mice.[51] 
Penn and First[52] reviewed development of cancer
following cyclosporine therapy compared with other
immunosuppressive regimens and found fewer skin
cancers in the cyclosporine group. 
In a recent study by Lerut, et al,[53] of 70 liver trans-
plant patients treated with cyclosporine monotherapy,
2 patients (2.8%) developed skin cancer over a 3 year
follow up period.
Corticosteroids inhibit proliferation of T cells.[5]
Steroids are often included in multi-drug immunosup-
pressive regimens. Karagas, et al,[54] reviewed chronic
use of oral steroids in non-OTRs and found that it was
associated with increased risk of SCC.
Mycophenolate mofetil (MMF) inhibits nucleotide
synthesis thus blocking T and B cell proliferation.[55]
Triemer, et al,[56] report one BCC in 106 renal transplant
patients treated with MMF, cyclosporine and corticos-
teroids compared with 1 SCC in 106 patients treated with
azathioprine, cyclosporine and steroids over a 6
month period.
OKT3 is an antithymocyte antibody used in
the induction phase of immunosuppression and
for steroid resistant rejection episodes.[57]
Stempfle, et al, report rapid growth of merkel cell
carcinoma during treatment of acute cardiac
allograft rejection with OKT3.[58] Similarly,
Lampros, et al,[13] reported increased risk of
development of skin cancers in heart transplant
recipients treated with OKT3. In contrast,
Oechslin, et al,[59] reported no association
between OKT3 induction and malignancy follow-
ing heart transplant.
Tacrolimus (FK 506), a metabolite of the fungus
Streptomyces tsukubaensis, suppresses T-lymphocytes
by inhibiting the production of IL-2, IL-3, IL-4, TNFa, and
GM-CSF.[45,60] Jain, et al, report a 2% incidence of skin
cancer over 6.5 years in patients treated with
tacrolimus.[61] Frezza, et al, reported lower incidence of
all tumors in liver transplant patients treated with
tacrolimus vs cyclosporine.[19] This is consistent with a
report that tacrolimus had antiproliferative effects in
murine tumor studies.[62]
Table 1 Factors Associated with SCC in Organ Transplant Recipients
Risk Factor Reference
Sun Exposure Lindelof, et al. (18)
HPV 5 and 8 Euvrard, et al., (40) Stockfelth, et al. (39)
Fair skin Lampros, et al., (10) Espana, et al. (13)
Heart transplant Jensen, et al., (16) Euvrard, et al. (11)
Intense immunosuppression Preciado, et al. (69) Euvrard, et al. (11)
Older age at transplant Jensen, et al., (16) Euvrard, et al. (11)
Male sex Naldi, et al., (17) Lampros, et al. (13)
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The macrolide rapamycin acts by inhibiting Target of
Rapamycin (mTOR), a key signaling protein that controls
activation of a number of other proteins that direct
progression of the cell cycle in response to pro-inflam-
matory cytokines.[63] Some studies suggest rapamycin
inhibits tumor growth while being immunosuppressive.
Furthermore, rapamycin was shown to inhibit several
UV-induced mechanisms involved in skin carcinogene-
sis. Preliminary clinical studies have reported a lower
incidence of skin malignancy in patients treated with
rapamycin compared to CsA from the time of transplan-
tation.[64]
Catastrophic Skin Cancer in Transplant 
Recipients
Local Disease Skin cancer is not only more
common in OTRs but also more serious. In some cases,
skin cancer in OTRs can be devastating in terms of quali-
ty of life, lost productivity and threatened mortality. Berg
and Otley diagnosed catastrophic cutaneous carcino-
matosis in patients with more than 10 NMSCs per year
or evidence of metastatic disease.[4] In addition, OTRs
with widespread severe actinic field damage, suffering
from hundreds of actinic keratoses mixed in with their
cancers might be best classified in this category
(Figure 1).[4,65]
Metastatic Disease Skin cancers metastasize
more frequently in OTRs.[66] In transit metastatic SCC
lesions are usually nondescript gray to flesh colored
subcutaneous papules that are not contiguous with the
primary lesion.[67] They are likely to represent spread
along lymphatic vessels and nerves, are a poor prognos-
tic indicator and represent a therapeutic challenge. In a
recent study, development of in transit metastases from
primary cutaneous SCC in OTRs was associated with
33% mortality at 2 years. 
Regional lymph nodes are the most common site of
metastases from primary skin cancer in transplant
patients. Euvard, et al, reported a series of 50 OTRs with
at least 1 SCC among whom 5 (10%) had an aggressive
course defined as multiple local recurrences with or
without lymph node metastasis.[68] In this series, all
aggressive tumors were located on the head with 3 in
kidney transplant recipients and 2 in heart transplant
recipients. Three patients (60%) developed nodal metas-
tases and died. 
Distant metastases from skin cancers in OTRs are
associated with a 29% relapse rate at 1 year and a
disease specific survival rate of 56% at 3 years.[66]
Preciado, et al, reviewed aggressive head and neck
cancers in OTRs.[69] There were 8 cases of primary
cutaneous SCC metastatic to parotid. Two were well
differentiated SCC, 5 were moderately differentiated and
1 was poorly differentiated SCC. In all cases primary
tumors were treated by surgical excision. 
Medical and Surgical Management of 
SCC in OTRs
While it is tempting to consider potential points of
intervention revealed by molecular studies in the future,
clinicians must contend with the growing number of
transplant recipients with skin cancer today. Currently,
our best approach relies on early detection through
thorough and sometimes frequent evaluation depending
on the extent of disease. Medical and surgical manage-
ment of skin cancer, particularly SCC in OTRs is a signif-
icant challenge for dermatologists. Members of the
Guidelines Committee of the International Transplant
Skin Cancer Collaborative reviewed ~300 articles
relevant to management of SCC in OTRs and combined
this review along with their collective experience in
management of SCC in OTRs to develop the first set of
guidelines of care for SCC in OTRs.[70] One of the key
points in managing SCC in OTRs is differentiating
between higher risk and lower risk lesions.
Lower Risk Lesions Less aggressive lesions were
characterized as those that were smaller size, static or
slowly growing, well demarcated and well differentiated
histologically. It was recommended that all less aggres-
sive SCC in OTRs should be managed by destructive or
excisional modalities depending on anatomic site.[70] It
was recommended that histologic analysis be performed
on all SCC in OTRs. Biopsy may be performed before or
at the time of treatment. Tangential excision for histolog-
ic analysis followed by immediate destruction may be
used and may be useful inpatients with multiple lesions
on the trunk and extremities.[70] Topical therapy with
imiquimod[71] or 5-fluorouracil[72] can be used on
superficial lesions and actinic keratoses[73-75]. In one
study, SCC in situ in 5 OTRs was effectively managed by
using these agents in combination.[76]
Higher Risk Lesions It is key to remember that
SCC in an OTR is considered to be a high-risk lesion as
defined by Rowe, et al.[2] When managing SCC in an
OTR it is important to differentiate those lesions that are
highest risk for recurrence or metastasis. Increased risk
may be associated with factors including rapid growth,
large diameter, location on ear, lip, or scalp, aggressive
histology, and recurrent SCC (Figure 2).[2,4,70] Careful
inspection of the surrounding skin to exclude the
presence of satellite lesions is necessary as is examina-
tion of the draining lymph nodes.[2,67,70] Aggressive
SCC confined to skin and soft tissue in OTRs should be
Figure 1. In cases of extensive field damage, it is 
difficult to distinguish between pre-malignant lesions
and superficial carcinomas.
812 CARUCCI THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
managed by Mohs micrographic surgery or standard
surgical excision.[70] Every attempt should be made to
achieve clear margins. Management of selected high-
risk lesions is summarized in Table 2.
Vandeghinste, et al, first reported the cessation of
new dysplastic skin lesions during acitretin treat-
ment.[77] Other studies have followed including one by
McNamara, et al, where five of 15 patients showed
reduction of new skin lesions on acitretin.[78] Bavinck, et
al, enrolled 44 renal transplant recipients in a random-
ized, double-blind, placebo-controlled trial to evaluate
chemoprevention with acitretin (30 mg/d).[79] Patients in
the treatment group developed significantly fewer new
SCCs (11% vs 47%) Yuan, et al, treated 15 renal trans-
plant recipients with progressive AKs, widespread warts
or recurrent skin cancers with acitretin (10-50
mg/day).[80] Fewer warts and AKs were noted in all
patients and fewer SCCs were seen in some patients
treated for longer than one year. Side effects in these
studies included dry mouth and dry eyes, mild hair loss,
elevated cholesterol and serum triglycerides, however
no effect on kidney function was observed.[78-80] A
recent study suggests that acitretin has no effect wound
healing after surgery.[81] Topical retinoids have the
potential for fewer side effects. In one study, a significant
decrease in the number of AKs was noted in patients
treated with adapalene.[82]
Reduction of immunosuppressive therapy may be
considered in cases of severe, life threatening skin
cancer.[4] In a recent series of 6 patients in whom skin
immunosuppressive therapy was discontinued,
4 patients experienced decreased development of skin
cancers.[83] Maintenance vs reduction of immunosup-
pression was addressed in a study of 9 renal transplant
recipients with aggressive cutaneous SCC invading
deep subcutis or muscle or with in transit or nodal metas-
tases.[84] A significant decrease in development of
metastases was noted in the group in whom immuno-
suppression was withdrawn. The authors postulate that
the degree of immunosuppression may act to switch a
locally growing SCC into a tumor with metastatic poten-
tial. In contrast, no conclusions regarding reduction of
immunosuppression could be drawn from a study of
OTRs with in transit metastases.[67] It must be remem-
bered that reducing immunosuppression may predis-
pose to rejection and therefore any decisions regarding
alteration of immunosuppression must be reached in
cooperation with the primary transplant physician. 
In some cases, sun exposed areas on transplant
patients are overrun with pre-malignant and malignant
skin lesions.[4,65] This is sometimes referred
to as “transplant hand”. It is not uncommon for
hands, arms and legs to be involved with
overwhelming numbers of lesions. In these
cases, topical therapies, destructive modali-
ties, and excision may be used in combination
or rotated in an attempt to achieve and
maintain control. In extreme cases, large
areas can be removed and resurfaced by split
thickness skin grafts. Physical therapy may be
required to optimize postoperative function.
Although not considered standard of care,
sentinel lymph node dissection (SLND) may
be considered in selected high risk SCC in the
appropriate setting. Reschly, et al, reviewed
the utility of sentinel lymph node dissection in patients
with high risk SCC on the trunk or extremities.[85] Histo-
logically positive nodes were found in four of nine
patients (44%) without clinical lymphadenopathy. Two of
the four patients with positive sentinel nodes died of
metastatic disease within 2 years. All five patients with
negative sentinel lymph nodes were alive without
disease at a median follow-up of 8 months. Altinyollar, et
al, reported on SLND in 20 patients with SCCs greater
than 2 cm on the lip without clinically appreciable lymph
nodes.[86] Nodal disease was identified in three patients
(16.6%).
In transit metastases from primary cutaneous SCC
present a significant challenge.[67] The presence of in
transit metastatic disease is a poor prognostic indicator.
In a recent study, OTRs with in transit metastases had
worse prognosis than non-OTRs. At 2 years follow up,
33% of OTRs showed no evidence of disease (NED),
33% were dead from disease and 33% were alive with
disease. All patients alive with disease had progressed
to nodal or distant metastases. Eighty percent of the
non-OTRs were NED at 2 years with 20% alive with local 
Figure 2. A large, rapidly growing, recurrent SCC falls into the
category of highest risk for metastasis.
Table 2      Management of Highest Risk SCC in OTRs
Tumor Characteristic Management
Invasive SCC MMS or Excision
Aggressive histology MMS or Excision
Perineural SCC MMS or Excision followed by XRT
High risk anatomic site MMS or Excision
Large tumor MMS or Excision
Recurrent cancer MMS or Excision
In transit metastases Excision, XRT, Retinoids, Decrease immunosuppression 
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recurrence. No non-OTRs were dead from disease
and none had progressed to nodal or distant metas-
tases. Patients were managed with varying combinations
of surgery and XRT. Immunosuppression was reduced in
some transplant patients. No conclusions could be
drawn with respect to optimal management however it
was clear that a multidisciplinary approach with careful
coordination between dermatologists, dermatopatholo-
gists, dermatologic surgeons, surgical and medical
oncologists and transplant physicians is necessary to
optimize outcome.
Martinez reviewed the literature regarding the use of
chemotherapy in HNSCC and proposed adaptation of
key management concepts in cases of advanced locore-
gional and metastatic SCC in OTRs.[87] In one phase 2
study, 39 patients were treated with IFN-α, retinoic acid,
and cisplatin.[88] The complete response rate was 17%
with patients having locally advanced disease respond-
ing better than patients with metastatic disease (67%
vs 17%). 
Longitudinal Dermatologic Care in Transplant
Recipients
Christensen et al, described the advantages and
disadvantages of various approaches of addressing the
needs of transplant recipients.[89] The utility of a multi-
disciplinary transplant clinic that includes transplant
surgeons, nephrologists, hepatologists, cardiologists,
endocrinologists, hypertension specialists, psychiatrists
and dermatologists was discussed. Some physicians set
aside practice sessions specifically for transplant
patients while others simply integrate their transplant
patients into their daily practice routine. Regardless of
the model used, key issues include enhancement of
communication between various members of the health
care team, insuring access to dermatologists for timely
evaluation of suspicious lesions and development of
educational programs directed towards patients and
colleagues, particularly transplant physicians and nurse
coordinators.[89] There are advantages and disadvan-
tages to each model based on the special needs and
frequent follow up usually required.[4] Patients with
multiple or severe life threatening cancers may need to
be followed as frequently as every 1-2 months while
those with skin type greater than III or patients with no
history of actinic keratoses or skin cancers may be
evaluated annually. Follow up should include evaluation
of previously treated areas for signs of recurrence and
careful examination of draining lymph nodes to exclude
regional disease.
As the number of solid organ transplants continues
to rise so too will the number of skin cancers in OTRs.
Dermatologists will be called upon to manage their skin
cancers and to develop novel therapeutic and preventa-
tive strategies. 
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